Stock Analiz

Xtant Medical Holdings, Inc. XTNT

Medical/Dental Instruments · data as of November 13, 2026

$0.27Market cap $38M
Open the interactive analysis →

Xtant Medical Holdings, Inc. (XTNT) is a healthcare company listed in the US with a market value of about $38M. In the twelve months to June 30, 2026 it had revenue of $110M and net income of -$11M, a net margin of -10.2%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (1/5).

Key numbers: 5-year revenue growth of 20% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% above the current price.

About Xtant Medical

Xtant Medical is listed in the US and classified in medical/dental instruments. Revenue went from $35M in 2014 to $134M in 2025, growth of about 12.9% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 59% over three years (dilution for shareholders). It spends 2% of revenue on research and development.

Score: 1.6 / 5

Value1/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.3
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1.8%
Shareholder yield0.0%
Intrinsic value vs. price+99%

Growth and quality

Revenue growth (1 yr)14.2%
Revenue growth (5 yrs, per year)20.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-6.6%
ROIC (5-yr avg.)-6.6%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$110M$134M$117M$91M$58M$55M$53M$65M$72M$83M$90M
Net income-$11M$5M-$16M$660000-$8M-$5M-$7M-$8M-$70M-$52M-$19M
Free cash flow-$696000$10M-$16M-$11M-$7M-$2M-$2M-$1M$588000-$2M-$20M
EPS (diluted)$-0.08$0.03$-0.12$0.01$-0.09$-0.06$-0.25$-0.63$-5.97$-34.76$-18.46
Net margin-10.2%3.7%-14.0%0.7%-14.6%-8.8%-13.2%-12.7%-97.1%-63.4%-21.7%
ROIC—7.5%-12.2%-10.7%-11.2%-6.4%-1.8%-5.2%-138.9%-47.7%-5.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Xtant Medical stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 99% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Xtant Medical pay a dividend?

Not currently.

Is Xtant Medical a good stock to buy?

We do not give buy or sell advice. Xtant Medical scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.